ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: FR-PO080

Crossover Study Comparing Bioavailability of Captisol-Enabled (CE) Iohexol Injection with Reference Iohexol Injection in Healthy Subjects

Session Information

  • AKI: Clinical Outcomes, Trials
    November 08, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials

Authors

  • Marschke, Keith, Ligand Pharmaceuticals Incorporated, San Diego, California, United States
  • Antle, Vincent, Ligand Pharmaceuticals Incorporated, San Diego, California, United States
  • Vajda, Eric G., Ligand Pharmaceuticals Incorporated, San Diego, California, United States
  • Zhi, Lin, Ligand Pharmaceuticals Incorporated, San Diego, California, United States
  • Cushing, Daniel, Medical and Regulatory Affairs, Phoenixville, Pennsylvania, United States
  • Pipkin, James, Ligand Pharmaceuticals Incorporated, San Diego, California, United States
Background

Iodinated contrast agents may place patients with certain risk factors at an increased risk for acute kidney injury during cardiac imaging procedures.1 Studies in renally-compromised mice and rats demonstrated that the addition of sulfobutylether β-cyclodextrin (Captisol®) to a clinically administered dose of Iohexol significantly reduced renal pathology scores, and increased survival in rats from 50% to 88%.2 A Phase 1, single-center, randomized, double-blind, two-period crossover study was conducted to determine relative bioavailability of CE-Iohexol and a reference Iohexol injection (OMNIPAQUE™) after intravenous (IV) administration in healthy adults.

Methods

A total of 24 subjects were enrolled in the study as 2 groups of 12 subjects in 2 treatment periods. Subjects received each of the following treatments as a single IV dose (80 mL infused over 20 seconds): CE-Iohexol -755 mg/mL iohexol (350 mgI/mL)/50 mg CAPTISOL/mL; OMNIPAQUE - 755 mg/mL iohexol (350 mgI/mL). Serial blood samples were collected for Iohexol plasma concentration determination, and safety was assessed during the 48 hours following each dose. Subjects were discharged on day 3.

Results

22 subjects completed the study; 2 subjects were withdrawn for technical reasons. Bioequivalence was demonstrated by calculation of geometric mean ratios (GMR) between CE-Iohexol and OMNIPAQUE for key pharmacokinetic parameters. GMR of the area under the concentration-time curve for time 0-infinity (AUC0-inf) was 1.00 (90% confidence interval [CI], 0.98-1.02). GMR of the maximum concentration (Cmax) was 1.00 (90% CI, 0.95-1.06). Other PK parameters, including time to maximum observed concentration (Tmax), half-life (t½) and elimination rate constant (Kel) were similar between treatments. All treatment-emergent adverse events during the study were mild to moderate in severity. No subject had a serious adverse event or discontinued from the study due to an adverse event.

Conclusion

The observed PK profile supports clinical development of CE-Iohexol as a next-generation contrast agent with a reduced risk of renal toxicity (NCT03869983).
1 McCullough PA, et al. J Am College of Cardiology 2016;68:1465-73
2 Rowe ES, et al. J Neuroimaging. 2016;26:511-518.

Funding

  • Commercial Support – Ligand Pharmaceuticals Incorporated